Document is current
Any future updates will be listed below
-
Authors
Ishii, Takaya https://orcid.org/0000-0001-6026-8664
Wang, Tao
Shibata, Kazuki
Nishitani, Shota
Yamanashi, Takehiko https://orcid.org/0000-0002-3881-8997
Wahba, Nadia E.
Seki, Tomoteru https://orcid.org/0000-0003-2593-7118
Thompson, Kaitlyn J.
Yamanishi, Kyosuke
Nishiguchi, Tsuyoshi
Shimura, Akiyoshi https://orcid.org/0000-0003-0806-4423
Aoyama, Bun
Gorantla, Nipun
Phuong, Nathan J. https://orcid.org/0009-0003-8374-782X
Nguyen, Hieu D.
Santiago, Therese A.
Nishizawa, Yoshitaka
Nagao, Takaaki
Howard, Mathew A. III
Kawasaki, Hiroto
Hino, Kyosuke https://orcid.org/0009-0000-4681-9730
Ikeda, Atsushi
Snyder, Michael P.
Shinozaki, Gen https://orcid.org/0000-0001-6129-2789
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH119165)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (AG084710)
- License Information
-
More Information
Article History
Received: 3 December 2025
Revised: 3 July 2026
Accepted: 28 July 2026
First Online: 5 August 2026
Ethics
Competing interests: TI, KS, KH, and AI are employees of Sumitomo Pharma Co., Ltd. TI, KH, and AI are currently affiliated with RACTHERA Co., Ltd. GS has pending patents as follows: “Epigenetic Biomarker of Delirium Risk” in the PCT Application No. PCT/US19/51276, in the PCT Application No. PCT/US21/63166 and in U.S. Provisional Patent No. 62/731599; “Non-invasive device for predicting and screening delirium” in the PCT application no. PCT/US2016/064937 and in US provisional patent no. 62/263,325; “Prediction of patient outcomes with a novel electroencephalography device,” in US provisional patent no. 62/829,411; “DEVICES, SYSTEMS, AND METHOD FOR QUANTIFYING NEURO-INFLAMMATION” in the US Patent Application No. 63/124,524. MPS is a cofounder and scientific advisor of Crosshair Therapeutics, Exposomics, Filtricine, Fodsel, iollo, InVu Health, January AI, Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, Personalis, Protos Biologics, Qbio, RTHM, SensOmics. MPS is a scientific advisor of Abbratech, Applied Cognition, Enovone, Jupiter Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, TranscribeGlass, WndrHLTH, Yuvan Research. MPS is a cofounder of NiMo Therapeutics. MPS is an investor and scientific advisor of R42 and Swaza. MPS is an investor in Repair Biotechnologies. All other authors declare no conflict of interest.
